FDAFDA PCAC reviews BPC-157, KPV, TB-500, MOTS-c (Jul 23) and DSIP, Semax, Epitalon (Jul 24, 2026) for 503A compounding eligibilityUPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORY12 peptides removed from FDA Category 2 (Apr 23, 2026) — removal is not approval; all remain pending PCAC reviewREGULATORYNo formal FDA reclassification published — no restricted peptide is legal to compound; 5 more peptides go to PCAC before Feb 2027RESEARCHA Real-world Study of Treatment Retention and Adherence to Secukinumab in Patients With Plaque Psoriasis (PsO) With or Without Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) Co-therapy [NCT07881783]RESEARCHStudy to Evaluate the Dose-Dependent Effect of Tirzepatide on Gastric Emptying in Adult Patients With Type 1 Diabetes [NCT07951658]RESEARCHA Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity [NCT06037252]RESEARCHA Study to Learn About the Study Medicine Called Rimegepant in Adults When Used for the Prevention of Chronic Migraine [NCT07729462]RESEARCHHypersensitivity to Amylin in Post-Traumatic Headache [NCT07340775]RESEARCHEffects of Tirzepatide on Corneal Nerve Morphology and Other Ocular Parameters in Adults With Obesity [NCT07950371]NEWSSTAT+: Peptide market poised to explode with new Hims and Noom launchesRESEARCHAlleviating Carbohydrate Counting for Patients With Type-1 Diabetes Using a Closed Loop System With Weekly Subcutaneous Semaglutide [NCT06387199]RESEARCHWeight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity [NCT07423481]RESEARCHSEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years [NCT07845994]FDAFDA PCAC reviews BPC-157, KPV, TB-500, MOTS-c (Jul 23) and DSIP, Semax, Epitalon (Jul 24, 2026) for 503A compounding eligibilityUPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORY12 peptides removed from FDA Category 2 (Apr 23, 2026) — removal is not approval; all remain pending PCAC reviewREGULATORYNo formal FDA reclassification published — no restricted peptide is legal to compound; 5 more peptides go to PCAC before Feb 2027RESEARCHA Real-world Study of Treatment Retention and Adherence to Secukinumab in Patients With Plaque Psoriasis (PsO) With or Without Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) Co-therapy [NCT07881783]RESEARCHStudy to Evaluate the Dose-Dependent Effect of Tirzepatide on Gastric Emptying in Adult Patients With Type 1 Diabetes [NCT07951658]RESEARCHA Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity [NCT06037252]RESEARCHA Study to Learn About the Study Medicine Called Rimegepant in Adults When Used for the Prevention of Chronic Migraine [NCT07729462]RESEARCHHypersensitivity to Amylin in Post-Traumatic Headache [NCT07340775]RESEARCHEffects of Tirzepatide on Corneal Nerve Morphology and Other Ocular Parameters in Adults With Obesity [NCT07950371]NEWSSTAT+: Peptide market poised to explode with new Hims and Noom launchesRESEARCHAlleviating Carbohydrate Counting for Patients With Type-1 Diabetes Using a Closed Loop System With Weekly Subcutaneous Semaglutide [NCT06387199]RESEARCHWeight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity [NCT07423481]RESEARCHSEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years [NCT07845994]

仅供研究使用。 完整免责声明 →

堆栈库

Triple GH Stack

GH Optimizationadvanced

88

协同作用

88
Share
肽类

3

平均每日mcg

957

级别

advanced

添加时间

May 17, 2026

概述

The Triple GH Stack amplifies the classic CJC-1295 + Ipamorelin protocol with Sermorelin, adding a third GHRH-pathway stimulant to maximize pituitary priming and increase the duration of GH stimulation beyond what CJC-1295 alone provides. Sermorelin is the shortest functional GHRH analog — a 29-amino acid truncated version of native GHRH. Where CJC-1295 provides a longer-acting GHRH signal, Sermorelin provides a more physiologically rapid, native-pattern pulse. Together they create a layered stimulation pattern: Sermorelin fires first with a sharp, natural signal, while CJC-1295 extends and sustains the pituitary response over a longer window. Ipamorelin continues to provide ghrelin-pathway amplification, ensuring the pituitary primed by CJC-1295 and Sermorelin releases its maximum GH payload with each pulse. The result is higher peak GH secretion and more frequent physiological pulses throughout the day and night. The 5-days-on/2-days-off cycling on Sermorelin (typically weekdays, off weekends) preserves receptor sensitivity on the GHRH pathway and prevents the tachyphylaxis that can occur with continuous stimulation. This stack is used by advanced practitioners seeking maximum GH axis stimulation without exogenous HGH. Blood work monitoring (IGF-1, fasting glucose) every 6–8 weeks is essential.

给药方案

CJC-1295

Every day· subcutaneous

了解更多关于CJC-1295 →

300 mcg

每剂

Ipamorelin

Every day· subcutaneous

了解更多关于Ipamorelin →

300 mcg

每剂

Sermorelin

5 days on/2 off· subcutaneous

了解更多关于Sermorelin →

500 mcg

每剂

目标与证据

Maximum GH outputAnti-agingBody compositionLean muscleRecovery
证据等级:人体数据

警告

  • Multi-GHRH stacking increases risk of pituitary receptor downregulation. Cycle carefully and monitor IGF-1 levels.

Comments

Sign in to join the discussion

免责声明: 此堆栈由社区提交,仅供研究用途。Peptide Contacts不对提交的堆栈的安全性或有效性进行验证。使用任何肽类协议前,请务必咨询合格的医疗专业人员。